Search results
Showing 61 to 75 of 196 results for early or locally advanced breast cancer
with 40 Gy in 15 fractions over 3 weeks in people with early or locally advanced invasive breast...
NICE is unable to make a recommendation on sacituzumab govitecan (Trodelvy) for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments in adults. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1089
NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating hormone receptor-positive HER2-low metastatic breast cancer in adults after 2 or more endocrine treatments. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1112
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)
Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children.
women:- Is neoadjuvant endocrine therapy safe in premenopausal women with early breast cancer? Any explanatory...
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]
Discontinued Reference number: GID-TAG403
Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults.
This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.
benefit for neoadjuvant endocrine therapy in postmenopausal women with early breast cancer? Any explanatory...
NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging
Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)
NICE has developed a medtech innovation briefing (MIB) on Signatera for detecting molecular residual disease from solid tumour cancers .
View a complete list of all our guidance, NICE advice and quality standards currently in development
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer (HTG642)
Evidence-based recommendations on Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer.
Caris Molecular Intelligence for guiding cancer treatment (MIB120)
NICE has developed a medtech innovation briefing (MIB) on Caris Molecular Intelligence for guiding cancer treatment .
NG101/1 Question Surgery to the breast:- What is the optimum tumour-free margin width after breast-conserving surgery for...